advertisement

Oculus

11.1 General management, indication (23)

Showing records 1 to 23

Display all abstracts in classification 11.1 General management, indication

Search within classification 11.1 General management, indication
84615 Secondary Neuroprotection in Glaucoma by Reduction of Intraocular Pressure
Unterlauft JD
Klinische Monatsblätter für Augenheilkunde 2020; 237: 150-157
84728 Nanotechnology for Medical and Surgical Glaucoma Therapy-A Review
Occhiutto ML
Advances in Therapy 2020; 37: 155-199
84463 Treatment choices for newly diagnosed primary open angle and ocular hypertension patients
Garg A
Eye 2020; 34: 60-71
84465 10-year trends in English primary care glaucoma prescribing
Hogg HDJ
Eye 2020; 34: 192-196
84667 Systematic reviews and randomised controlled trials on open angle glaucoma
Wormald R
Eye 2020; 34: 161-167
84831 Comparing glaucoma medications and general demographics in a sample of glaucoma patients treated in private practice with nationwide registry data in Finland
Parkkari M
Acta Ophthalmologica 2019; 0:
84920 Prescribing trends of glaucoma drugs in six major cities of China from 2013 to 2017
Yu L
PLoS ONE 2020; 15: e0227595
85065 Baseline characteristics of participants in the Treatment of Advanced Glaucoma Study (TAGS): A multicentre randomised controlled trial
King AJ
American Journal of Ophthalmology 2020; 213: 186-194
84463 Treatment choices for newly diagnosed primary open angle and ocular hypertension patients
Gazzard G
Eye 2020; 34: 60-71
84920 Prescribing trends of glaucoma drugs in six major cities of China from 2013 to 2017
Ding K
PLoS ONE 2020; 15: e0227595
84667 Systematic reviews and randomised controlled trials on open angle glaucoma
Virgili G
Eye 2020; 34: 161-167
84831 Comparing glaucoma medications and general demographics in a sample of glaucoma patients treated in private practice with nationwide registry data in Finland
Taipale J
Acta Ophthalmologica 2019; 0:
85065 Baseline characteristics of participants in the Treatment of Advanced Glaucoma Study (TAGS): A multicentre randomised controlled trial
Hudson J
American Journal of Ophthalmology 2020; 213: 186-194
84728 Nanotechnology for Medical and Surgical Glaucoma Therapy-A Review
Maranhão RC
Advances in Therapy 2020; 37: 155-199
84465 10-year trends in English primary care glaucoma prescribing
Connor A
Eye 2020; 34: 192-196
84920 Prescribing trends of glaucoma drugs in six major cities of China from 2013 to 2017
Luo L
PLoS ONE 2020; 15: e0227595
85065 Baseline characteristics of participants in the Treatment of Advanced Glaucoma Study (TAGS): A multicentre randomised controlled trial
Fernie G
American Journal of Ophthalmology 2020; 213: 186-194
84728 Nanotechnology for Medical and Surgical Glaucoma Therapy-A Review
Costa VP
Advances in Therapy 2020; 37: 155-199
84667 Systematic reviews and randomised controlled trials on open angle glaucoma
Azuara-Blanco A
Eye 2020; 34: 161-167
84831 Comparing glaucoma medications and general demographics in a sample of glaucoma patients treated in private practice with nationwide registry data in Finland
Uusitalo H
Acta Ophthalmologica 2019; 0:
84728 Nanotechnology for Medical and Surgical Glaucoma Therapy-A Review
Konstas AG
Advances in Therapy 2020; 37: 155-199
84920 Prescribing trends of glaucoma drugs in six major cities of China from 2013 to 2017
Yu Z
PLoS ONE 2020; 15: e0227595
85065 Baseline characteristics of participants in the Treatment of Advanced Glaucoma Study (TAGS): A multicentre randomised controlled trial
Burr J; Azuara-Blanco A; Sparrow J; Barton K; Garway-Heath DF; Kernohan A; Maclennan G;
American Journal of Ophthalmology 2020; 213: 186-194

Issue 21-1

Select Issue


advertisement

Oculus